CD38 and Miyoshi myopathy: FT538, engineered to express hnCD16, IL-15, and KO for CD38 (hnCD16 + IL-15RF + CD38 KO), is tested in two Phase I studies in AML, MM, and monocytic leukemia (NCT04614636 and NCT04714372, Additional file 2: Table S2 rows 24–25; Additional file 4: Table S4 rows 6–7) and in solid tumors (NCT05069935, Additional file 2: Table S2 row 26; Additional file 4: Table S4 row 8).